Eli Lilly And Co (LLY) Position Reduced by Mitchell Sinkler & Starr PA
Mitchell Sinkler & Starr PA reduced its position in shares of Eli Lilly And Co (NYSE:LLY) by 24.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 8,408 shares of the company’s stock after selling 2,658 shares during the quarter. Mitchell Sinkler & Starr PA’s holdings in Eli Lilly And Co were worth $973,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of LLY. FMR LLC raised its holdings in Eli Lilly And Co by 172.9% during the 2nd quarter. FMR LLC now owns 1,188,301 shares of the company’s stock valued at $101,398,000 after buying an additional 752,864 shares during the last quarter. Pensionfund Sabic bought a new stake in Eli Lilly And Co during the 3rd quarter valued at $3,112,000. Pensionfund DSM Netherlands bought a new stake in Eli Lilly And Co during the 3rd quarter valued at $4,292,000. Norman Fields Gottscho Capital Management LLC bought a new stake in Eli Lilly And Co during the 3rd quarter valued at $206,000. Finally, CENTRAL TRUST Co raised its holdings in Eli Lilly And Co by 1.7% during the 3rd quarter. CENTRAL TRUST Co now owns 53,103 shares of the company’s stock valued at $5,698,000 after buying an additional 886 shares during the last quarter. Institutional investors own 76.83% of the company’s stock.
A number of equities research analysts recently commented on LLY shares. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a report on Wednesday, December 5th. Guggenheim assumed coverage on shares of Eli Lilly And Co in a research report on Monday, October 8th. They set a “buy” rating on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $128.00 price objective on shares of Eli Lilly And Co in a research report on Wednesday, October 17th. Wolfe Research assumed coverage on shares of Eli Lilly And Co in a research report on Tuesday, October 23rd. They set a “market perform” rating and a $119.00 price objective on the stock. Finally, Societe Generale set a $106.00 price objective on shares of Eli Lilly And Co and gave the company a “hold” rating in a research report on Wednesday, November 7th. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Eli Lilly And Co has an average rating of “Buy” and a consensus target price of $113.24.
Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.04. The firm had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The company’s revenue was up 7.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.05 EPS. On average, analysts forecast that Eli Lilly And Co will post 5.58 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be given a $0.645 dividend. The ex-dividend date is Thursday, February 14th. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.24%. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.
In other news, major shareholder Lilly Endowment Inc sold 136,577 shares of the company’s stock in a transaction dated Thursday, January 17th. The shares were sold at an average price of $118.33, for a total value of $16,161,156.41. Following the sale, the insider now directly owns 117,866,748 shares of the company’s stock, valued at approximately $13,947,172,290.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Eli & Co Lilly sold 700,000 shares of the company’s stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $14.00, for a total transaction of $9,800,000.00. Following the completion of the sale, the insider now directly owns 3,148,647 shares in the company, valued at $44,081,058. The disclosure for this sale can be found here. Insiders sold a total of 1,716,383 shares of company stock worth $126,899,574 over the last ninety days. Insiders own 0.11% of the company’s stock.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: Quick Ratio
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.